SCHEMBL23256551

SCHEMBL23256551

N#Cc1ccc2nc(NC(=O)Nc3ccnc(Cl)c3)sc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.60
▸ GSK3B P49841 1/20 0.52
▸ SMARCA2 P51531 3/20 0.51
▸ SMARCA4 P51532 3/20 0.51
▸ HSD17B10 Q99714 8/20 0.51
▸ DYRK1B Q9Y463 2/20 0.49
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ CXCR2 P25025 1/20 0.47
▸ RAF1 P04049 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23256871 0.85 SMN1; SMN2 (0.66) DYRK1AGSK3BHSD17B10DYRK1BMEN1
SCHEMBL21568343 0.85 DYRK1A (0.59) DYRK1AGSK3BHSD17B10DYRK1BMEN1
SCHEMBL21568323 0.84 DYRK1A (0.65) DYRK1AGSK3BHSD17B10DYRK1BMEN1
SCHEMBL21568259 0.84 LMNA (0.66) DYRK1AGSK3BHSD17B10DYRK1BMEN1
SCHEMBL23256883 0.83 DYRK1A (0.66) DYRK1AGSK3BHSD17B10DYRK1BMEN1
SCHEMBL23256870 0.82 DYRK1A (0.70) DYRK1AGSK3BDYRK1BMEN1KMT2A
SCHEMBL21568130 0.81 DYRK1A (0.65) DYRK1AGSK3BHSD17B10DYRK1BMEN1
SCHEMBL21568073 0.81 DYRK1A (0.62) DYRK1AGSK3BHSD17B10DYRK1BMEN1
SCHEMBL23256895 0.80 DYRK1A (0.68) DYRK1AGSK3BDYRK1BMEN1KMT2A
SCHEMBL21568123 0.80 DYRK1A (0.65) DYRK1AGSK3BHSD17B10DYRK1BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2021-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731985-B2 Compositions and methods for treating cancer VHL, TP53, NUDT1 DYRK1A 4664/4885GSK3B 4096/4885SMARCA2 3223/4885
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER VHL, TP53, NUDT1 DYRK1A 4618/4885GSK3B 4200/4885SMARCA2 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback